医学
心脏病学
内科学
二尖瓣反流
功能性二尖瓣反流
二尖瓣
相伴的
肥厚性心肌病
梗阻性肥厚性心肌病
心肌病
梗阻性心肌病
心力衰竭
心房颤动
退行性疾病
二尖瓣关闭不全
并发症
二尖瓣反流
心脏病
二尖瓣环成形术
心电图
治疗方法
疾病
作者
Yu Wang,Xiangjuan Liu,Lianyue Ma,Yan Liu,Yuan Cao,Guipeng An,Fangfang Liu,Mei Dong
标识
DOI:10.1016/j.jaccas.2026.107398
摘要
BACKGROUND: Transcatheter edge-to-edge mitral valve repair (M-TEER) has been demonstrated as an effective therapeutic option for patients with obstructive hypertrophic cardiomyopathy (oHCM) and concomitant degenerative mitral regurgitation. Mavacamten is a mechanism-based therapy for oHCM that can improve hemodynamics. However, clinical evidence on the concomitant use of mavacamten and M-TEER remains limited, and related case reports are scarce. CASE SUMMARY: We present the case of a 79-year-old woman with symptomatic severe oHCM complicated by mitral valve prolapse, aortic stenosis, and secondary tricuspid regurgitation. Under the combined strategy of mavacamten and M-TEER, the patient experienced significant improvements in both symptoms and hemodynamics. DISCUSSION: In oHCM, identifying the underlying mechanism of mitral regurgitation is crucial for therapeutic decision-making. Direct M-TEER in the setting of severe left ventricular outflow tract obstruction may carry specific risks and uncertainties. A stepwise strategy using mavacamten followed by M-TEER may reduce procedural risk while achieving more stable clinical and hemodynamic improvement. TAKE-HOME MESSAGE: For oHCM patients with concomitant degenerative mitral regurgitation, the combined treatment of mavacamten and M-TEER represents a potential therapeutic option with complementary mechanisms.
科研通智能强力驱动
Strongly Powered by AbleSci AI